02 May 2003 : Case report
Effect of 5-aminoisoquinolinone, a water soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase, in a rodent model of lung injury
L. Dugo, S. Cuzzocrea, M. McDonald, E. Mazzon, I. Serraino, M. Threadgill, A. Caputi, C. ThiemermannMed Sci Monit 2003; 9(1): 22-0 :: ID: 15069
Abstract
Poly (ADP-ribose) polymerase (PARP), a nuclear enzyme activated by strand breaks in DNA, plays an important role in the tissue injury associated with ischaemia-reperfusion injury and inflammation. Continuous or excessive activation of PARP produces extended chains of ADP-ribose on nuclear proteins and results in a substantial depletion of intracellular NAD+ and subsequently ATP, which may lead to cell death [1,2]. Production of reactive oxidants such as hydrogen peroxide, superoxide anions, hydrogen peroxide or hydroxyl radical at the site of inflammation contributes of tissue damage [3].The aim of the present study was to evaluate the effects of a novel and potent inhibitor of PARP activity, 5-Aminoisoquinolinone (5-AIQ), on neutrophil recruitment in the acute inflammation induced by zymosan-activated plasma in mice. Intra-thoracic administration of zymosan-activated plasma leads to an increase in neutrophil infiltration of the lung at 24hr. The potent PARP inhibitor 5-AIQ reduced the degree of lung injury and attenuated the expression of P-selectin and ICAM-1 as well as the recruitment of neutrophils into the lung during acute inflammation. The up-regulation/expression of P-selectin and ICAM-1 in human endothelial cells exposed to oxidative stress (peroxynitrite) or to a pro-inflammatory cytokine (tumor necrosis factor alpha, TNF-a) was also attenuated by 5-AIQ.These findings provide the first evidence that the activation of PARP participates in neutrophil-mediated lung injury by regulating the expression of P-selectin and ICAM-1.References: 1.Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG, Cochrane CG: J Clin Invest, 1986; 77: 1312-20 2.Thies RL, Autor AP: Arch Biochem Biophys, 1991; 286: 353-63 3.Cuzzocrea S, Costantino G, Mazzon E, Caputi AP: Br J Pharmacol, 1999; 126: 407-14
Keywords: 5-aminoisoquinolinone pleurisy, oxygen radicals, poly (ADP-ribose) synthetase, zymosan-activated plasma
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952